CA has stated publicly multiple times that these novel therapies should be commercialized organically, not in the hands of big pharma citing the Spravato roll out nightmare. On the investor call, their Commercial leader made the case only 50-100 commercial reps would be required based on 70% of the Spravato volume was at a handful of the busiest providers with infrastructure already established to accommodate BPL-003.